Samuel Bjork
Directeur/Membre du Conseil chez EpiBiologics, Inc.
Profil
Samuel Bjork is currently a Director at PetMedix Ltd., Bonum Therapeutics, Inc., and EpiBiologics, Inc. He is also a Partner at Digitalis Ventures LLC.
Previously, he worked as a Strategic Advisor at Columbia Technology Ventures.
He received his undergraduate degree from Harvard University and his graduate degrees from the University of Oxford and the University of Cambridge.
Postes actifs de Samuel Bjork
| Sociétés | Poste | Début |
|---|---|---|
Digitalis Ventures LLC
 Digitalis Ventures LLC Investment ManagersFinance Digitalis Ventures LLC (Digitalis Ventures) is a venture capital firm founded in 2016 by Geoffrey W. Smith. The firm is headquartered in New York. | Private Equity Investor | 01/01/2017 |
Bonum Therapeutics, Inc.
 Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
EpiBiologics, Inc.
 EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Directeur/Membre du Conseil | 20/07/2023 |
PetMedix Ltd.
 PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Samuel Bjork
| Sociétés | Poste | Fin |
|---|---|---|
Columbia Technology Ventures
 Columbia Technology Ventures Investment ManagersFinance Columbia Technology Ventures (Columbia Ventures) is a venture capital subsidiary of The Trustees of Columbia University in The City of New York founded in 1982. The firm is headquartered in New York. | Consultant / Advisor | 01/02/2017 |
Formation de Samuel Bjork
| Harvard University | Undergraduate Degree |
| University of Oxford | Graduate Degree |
| University of Cambridge | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Digitalis Ventures LLC
Digitalis Ventures LLC Investment ManagersFinance Digitalis Ventures LLC (Digitalis Ventures) is a venture capital firm founded in 2016 by Geoffrey W. Smith. The firm is headquartered in New York. | Finance |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Commercial Services |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Commercial Services |
Columbia Technology Ventures
Columbia Technology Ventures Investment ManagersFinance Columbia Technology Ventures (Columbia Ventures) is a venture capital subsidiary of The Trustees of Columbia University in The City of New York founded in 1982. The firm is headquartered in New York. | Finance |
